Post by icemandios on Oct 28, 2021 12:44:27 GMT
Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors
EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device executive with extensive finance and operations experience at publicly traded and private companies.
Since 2018, she has served as the Chief Financial Officer of NatureWorks, LLC. Prior to that, she was the Chief Financial Officer at NxThera, Inc. From 2002 to 2012, she also served as the Chief Financial Officer of Tornier, NV, Spine Wave, Inc. and American Medical Systems, Inc. Additionally, she was Vice President/GM of Musculoskeletal Tissue Services at Medtronic, Inc. and started her career at Peat, Marwick, Mitchell & Co. Ms. Volkart has public company board experience, which includes the Memry Corporation, SonoSite, Inc. and Modular Medical, Inc. She is a Certified Public Accountant and received her B.S. in Accounting from the University of North Dakota and MBA from the University of Minnesota, Carlson School of Management.
Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, commented, “We are delighted to welcome another experienced healthcare executive to the Board of Directors. With her extensive background in growing healthcare companies, we believe Ms. Volkart’s contributions will prove beneficial across our organization. We look forward to leveraging her successful career as we continue to execute on our growth initiatives.”
Ms. Volkart commented, “I am delighted to join the Board of Directors at Antares Pharma and support their efforts as they continue to enhance their proprietary portfolio and partner business. I believe my healthcare experiences will support the overall growth strategy of the company. I appreciate the opportunity to join Antares at this juncture.”
About Antares Pharma
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA ® (desmopressin acetate) in the U.S. and expects to commercially launch TLANDO ® (testosterone undecanoate) in the U.S. pending final FDA approval.
EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device executive with extensive finance and operations experience at publicly traded and private companies.
Since 2018, she has served as the Chief Financial Officer of NatureWorks, LLC. Prior to that, she was the Chief Financial Officer at NxThera, Inc. From 2002 to 2012, she also served as the Chief Financial Officer of Tornier, NV, Spine Wave, Inc. and American Medical Systems, Inc. Additionally, she was Vice President/GM of Musculoskeletal Tissue Services at Medtronic, Inc. and started her career at Peat, Marwick, Mitchell & Co. Ms. Volkart has public company board experience, which includes the Memry Corporation, SonoSite, Inc. and Modular Medical, Inc. She is a Certified Public Accountant and received her B.S. in Accounting from the University of North Dakota and MBA from the University of Minnesota, Carlson School of Management.
Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, commented, “We are delighted to welcome another experienced healthcare executive to the Board of Directors. With her extensive background in growing healthcare companies, we believe Ms. Volkart’s contributions will prove beneficial across our organization. We look forward to leveraging her successful career as we continue to execute on our growth initiatives.”
Ms. Volkart commented, “I am delighted to join the Board of Directors at Antares Pharma and support their efforts as they continue to enhance their proprietary portfolio and partner business. I believe my healthcare experiences will support the overall growth strategy of the company. I appreciate the opportunity to join Antares at this juncture.”
About Antares Pharma
Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s FDA-approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA ® (desmopressin acetate) in the U.S. and expects to commercially launch TLANDO ® (testosterone undecanoate) in the U.S. pending final FDA approval.